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The mTOR pathway is a master regulator of cellular growth and metabolism. The biosynthetic and energetic
demand of rapidly proliferating cells such as cancer cells is met by metabolic adaptations such as an increased
glycolytic rate known as the Warburg effect. Herein, we characterize the anti-tumor effect of rapamycin in a
mouse model of T-cell lymphoma and examine the metabolic effects in vitro. The murine T-cell lymphoma line,
MBL2, and human cutaneous T-cell lymphoma (CTCL) lines, HH and Hut78, were used in syngeneic or standard
NSG mouse models to demonstrate a marked suppression of tumor growth by rapamycin accompanied by
inhibition of mTORC1/2. Analysis of the metabolic phenotype showed a substantial reduction in the glycolytic
rate and glucose utilization in rapamycin-treated lymphoma cells. This was associated with reduced expression of
glucose transporters and glycolytic enzymes in cultured cells and xenograft tumors. As a result of the decrease in
glycolytic state, rapamycin-treated cells displayed reduced sensitivity to low-glucose conditions but continued to
rely on mitochondrial oxidative phosphorylation (OXPHOS) with sensitivity to inhibition of OXPHOS. Taken
together, we demonstrate that rapamycin suppresses growth of T-cell lymphoma tumors and leads to a reduction
in aerobic glycolysis counteracting the Warburg effect of cancer cells.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are a rare form of non-
Hodgkin lymphoma originating in the skin. CTCL usually
follows a well-described course with limited skin disease in
the beginning and development of tumors and possibly
extracutaneous involvement in later stages (Hwang et al.
2008; Jawed et al., 2014a). Recurrent and refractory disease
often presents a challenge in the treatment of cutaneous
lymphoma (Kaplan et al 2014; Jawed et al., 2014b). Thus,
there is a need for more effective treatment options preventing
disease progression and relapse. A better understanding of
the pathophysiology and deregulated signaling networks
controlling growth and metabolism of lymphoma cells may
identify new treatment targets.
The mTOR (mechanistic or mammalian target of rapamycin)
pathway is a master regulator of cell growth and metabolism
(Zoncu et al. 2011). mTOR, a serine/threonine kinase, exists as
two distinct cellular complexes––mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2). Both complexes are large
multisubunit structures with a distinct set of functions and
downstream targets. The mTORC1 regulates cellular protein
synthesis and metabolism. In addition to controlling translation
and protein synthesis through phosphorylation of its well-
known downstream targets S6 kinase (S6K) and the eukaryotic
translation initiation factor 4E (eIF4E) binding protein 1 (4E-
BP1), recent data show that mTORC1 is an important regulator
of gene transcription controlling a range of metabolic processes
such as glycolysis and mitochondrial metabolism (Laplante and
Sabatini 2013).
Activation of mTOR has been shown in several human
cancers (Laplante and Sabatini 2012). Cancer cells show an
altered metabolic phenotype with increased utilization of
glucose and preferential conversion into lactate, which is
called aerobic glycolysis or the “Warburg effect” (Ward
and Thompson 2012). The result of this increased glycolytic
state is an abundance of biosynthetic building blocks.
Accumulating evidence supports a central role of mTOR in
inducing and/or maintaining the metabolic phenotype of
cancer cells, as several key glycolysis genes are regulated by
mTORC1 (Düvel et al. 2010).
The macrolide rapamycin is a potent inhibitor of mTORC1
(Brown et al. 1994; Sabatini et al. 1994; Sabers et al. 1995). In
contrast, mTORC2 is less sensitive to rapamycin with only
prolonged exposure showing inhibition of mTORC2 in some
cell types (Sarbassov et al. 2004; Sarbassov et al. 2006).
Overall, much less is known about upstream regulators and
downstream targets of mTORC2 among those are Akt (S473),
serum- and glucocorticoid-regulated kinase (SGK), and
protein kinase C (PKC). Through phosphorylation of those
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downstream effectors, mTORC2 is involved in the regulation
of cytoskeletal organization, metabolism, and survival (Cornu
et al. 2013).
Therapeutic targeting of the mTOR signaling pathway has
become an area of active investigation in cancer biology
(Laplante and Sabatini 2012). Numerous ongoing clinical
trials are investigating the therapeutic efﬁcacy of PI3K/AKT/
mTOR inhibitors in hematologic malignancies with response
rates of up to 30–40% in patients with T- and B-cell
lymphomas (Tasian et al. 2014 and Westin 2014).
Given the central role of mTOR in cancer growth and
metabolism, we sought to explore the anti-tumor activity of
rapamycin and its effect on tumor cell metabolism in
T-cell lymphoma. Using a recently described syngeneic
mouse model for cutaneous lymphoma (Wu et al. 2011)
along with a standard NSG mouse model for CTCL, we
were able to demonstrate that rapamycin possesses anti-
tumor activity. Moreover, we present evidence that the anti-
tumor effect is associated with a changed bioenergetic
phenotype of lymphoma cells counteracting the Warburg
effect.
RESULTS
Rapamycin suppresses growth of murine and human T-cell
lymphoma tumors in mouse skin
To determine whether rapamycin has growth suppressive
effects on T-cell lymphoma, we employed a recently
described syngeneic, inﬂammation-based T-cell lymphoma
transplant model recapitulating tumor development in CTCL
(Wu et al. 2011). Starting at day 6 after injection of cells at
which time all animals showed small tumors, 0.05%
rapamycin ointment was applied daily to the injected ears.
Treatment with rapamycin resulted in marked suppression
of tumor growth (Figure 1a). Isolated tumors of rapamycin-
treated animals showed decreased mTOR activity. The
phosphorylation level of S6K and S6 was signiﬁcantly lower
than in control animals. Interestingly, Akt also showed a
decreased level of phosphorylation of serine 473, which has
been shown to be a direct downstream target of mTORC2
(Figure 1b).
As tumor formation in the syngeneic model requires
induction of local inﬂammation, we wanted to rule out
any effects of rapamycin-mediated immunomodulation on
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Figure 1. Rapamycin suppresses growth of murine and human T-cell lymphoma tumors in mouse skin. (a)MBL2 cells were injected into the ear skin of C57BL/6
mice followed by a one-time application of DNFB. Starting on day 6, topical rapamycin (Rapamycin) or vehicle (Control) was applied daily until mice were killed
on day 12. Representative pictures and hematoxylin & eosin stains of tumors and ear thickness of animals treated with vehicle (C) and rapamycin (Rap) (n= 5
separate tumors from separate animals). (b) Suppression of mTOR pathway activity in MBL2 ear tumors. (c) MBL2 cells or (d) HH cells were injected
subcutaneously into ﬂanks of NSG mice followed by daily i.p. injection of vehicle or rapamycin as described in Materials and Methods. Shown are representative
pictures of tumors and the tumor weight (n=6–10 separate tumors). (e) Suppression of mTOR activity in HH tumors in rapamycin-treated animals. ***Po0.001.
The whiskers in the box plots represent the maximum and the minimum value.
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development and growth of MBL2 tumors in the immuno-
competent C57BL/6 background. MBL2 cells were injected
subcutaneously into ﬂanks of immunodeﬁcient SCID (NSG)
mice and rapamycin or vehicle was injected intraperitoneally
starting after small tumors were detectable (approximately
5×5mm). The rapamycin-treated animals showed a signiﬁ-
cant reduction in tumor mass compared with control animals
(Figure 1c), conﬁrming the growth-suppressive effect of
rapamycin on MBL2 tumors.
To conﬁrm the relevance of those ﬁndings for cutaneous
T-cell lymphoma, we employed a standard xenograft model
using the human CTCL cell line HH injected into NSG mice.
Treatment with rapamycin was started after small tumors had
developed (approximately 5×5mm). Rapamycin markedly
reduced the mass of HH xenograft tumors (Figure 1d) along
with a reduction in mTOR pathway activity in tumor tissue
(Figure 1e). Similar to MBL2 cells, we observed a decreased
phosphorylation of Akt at serine 473, indicating a reduced
activity of mTORC2 in addition to mTORC1. This is notable
as mTORC2 had initially been thought to be insensitive
to rapamycin (Sarbassov et al. 2004). More recent data,
however, suggest that some cell lines show rapamycin
sensitivity of mTORC2 signaling upon prolonged incubation
with rapamycin (Sarbassov et al. 2006). Overall, our data
demonstrate a substantial anti-tumor activity of rapamycin in
murine T-cell lymphoma, as well as human CTCL tumor
models.
Rapamycin suppresses proliferation and mTOR activity in T-cell
lymphoma cells
To further characterize the anti-tumor effect of rapamycin in the
mouse model, we determined the effect of rapamycin on
proliferation and cell cycle progression of lymphoma cells
in vitro. Incubation of MBL2, HH, and Hut78 cells with
rapamycin led to a marked decrease in their proliferation rate
(Figure 2a). Next, we examined the effect of rapamycin on cell
cycle progression. Cells were treated with rapamycin
for 24 hours after which cell cycle distribution was assessed.
We found a marked increase in cells in the G1 phase compared
with untreated cells (Figure 2b). The percentage of cells in
S and G2/M phases was also markedly reduced in the
rapamycin-treated population. The ability of rapamycin
to delay G1 progression and decrease proliferation in vitro
helps explain the observed effect of rapamycin on tumor growth.
The effect of rapamycin on proliferation and cell cycle
progression was associated with a decrease in mTOR path-
way activity as assessed by phosphorylation levels of S6K, S6,
and Akt. Interestingly, analogous to its effect on murine and
human lymphoma tumors, rapamycin decreased phosphor-
ylation of Akt at serine 473, a downstream target of mTORC2
(Figure 2c). Thus, in MBL2 and HH cells, rapamycin leads to
inhibition of both mTORC1 and mTORC2 in vitro and in
transplanted tumors in vivo.
Reduction in aerobic glycolysis and glucose uptake in cultured
murine and human T-cell lymphoma cells by rapamycin
Given the central role of mTOR signaling in regulating
cellular energy metabolism, we next asked whether inhibition
of mTOR by rapamycin resulted in changes of the bioener-
getic phenotype of lymphoma cells. Measuring the extra-
cellular acidiﬁcation rate (ECAR) as a marker for cellular
lactate production by aerobic glycolysis, we could demon-
strate a marked decrease in the glycolytic rate after rapamycin
treatment in MBL2 cells and both human CTCL cell lines––
HH and Hut78 (Figure 3a). At baseline, we observed a
signiﬁcantly decreased glycolytic rate in rapamycin-treated
cells. The addition of oligomycin, an inhibitor of mitochon-
drial ATP synthase and thus mitochondrial ATP generation,
led to a compensatory maximum increase in the glycolytic
rate in treated and untreated cells. However, the maximum
glycolytic rate was drastically reduced in treated cells,
suggesting an impaired glycolytic capacity of cells with
reduced mTOR activity. Addition of 2-deoxyglucose resulted
in complete inhibition of glycolysis, which was used to
determine how much of the extracellular acidiﬁcation was
due to glycolytic activity in cells.
Consistent with the decreased rate of extracellular acid-
iﬁcation indicating a reduction in aerobic glycolysis, we were
able to demonstrate a decreased lactate production of MBL2
and HH cells after incubation with rapamycin (Figure 3b).
Furthermore, we observed a reduction in glucose uptake,
indicating a decrease in glucose utilization in rapamycin-
treated cells (Figure 3c). The lack of a signiﬁcant decrease in
ATP levels indicates that the decreased glycolytic activity
matches the reduced bioenergetic demand after treatment
with rapamycin (Figure 3d). This suggest that inhibition of
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Figure 2. Rapamycin suppresses proliferation and mTOR activity in cultured
murine and human T-cell lymphoma cells. Cells were incubated with
rapamycin (15 nM) for 24 hours. (a) Determination of the proliferative rate and
(b) cell cycle analysis. Results are shown from one experiment as mean± SD
of triplicate measurements representative of at least three similar experiments;
**Po0.01. (c) Suppressed mTOR pathway activity after incubation with
rapamycin in MBL2 and HH cells.
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mTOR signaling in murine and human T-cell lymphoma cells
leads to reduced aerobic glycolysis with decreased glucose
utilization and lactate output.
Inhibition of mTOR reduces expression of glycolysis genes in
T-cell lymphoma cells and xenograft tumors
Given that rapamycin-treated cells displayed a reduced
glycolytic state, we asked whether rapamycin-treated cells
showed decreased expression of key enzymes of the
glycolytic pathway. Cells were treated with rapamycin for
24 hours followed by the detection of mRNA expression
levels of glucose transporters (GLUT1, GLUT3), hexokinase 2
(HK2), and lactate dehydrogenase α (LHDA). All four genes
showed a uniformly reduced expression in MBL2 cells after
incubation with rapamycin (Figure 4a). Interestingly, we
could not ﬁnd downregulated mRNA levels of GLUT1/3 in
HH cells despite the decreased glucose uptake (Figure 4b),
suggesting the involvement of post-transcriptional regulation
or other glucose transport mechanisms in those cells. Analysis
of GLUT1/3, HK2, and LDHA expression levels in xeno-
grafted HH tumors revealed a similar suppressive effect of
rapamycin in vivo compared with the previous in vitro studies.
Xenografted HH tumors showed reduced levels of GLUT3,
HK2, and LDHA in rapamycin-treated animals (Figure 4c).
This ﬁnding was conﬁrmed by western blot showing a
decrease in GLUT3, HK2, and LDHA (Figure 4d). The
difference in GLUT3 expression between HH cells and
tumors most likely reﬂects the difference in nutrient supply
between cultured cells with abundant nutrients compared
with tumor microenvironment.
Inhibition of mTOR promotes a metabolic phenotype with
decreased glucose dependency
Next, we sought to understand the functional consequences
of the changed metabolic state in rapamycin-treated lym-
phoma cells and whether it counteracts the Warburg effect.
As cancer cells mainly rely on aerobic glycolysis to meet their
bioenergetic demand, they should be sensitive to low-glucose
conditions. As rapamycin reduces the glycolytic state in
lymphoma cells, we asked whether rapamycin-treated cells
showed altered sensitivity to low-glucose conditions. Viability
of HH and Hut78 cells incubated in media with normal
(11mM), low (1 mM), and absent glucose (0 mM) was
assessed. Consistent with the observed metabolic phenotype
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Figure 3. Reduction in aerobic glycolysis and glucose uptake in cultured
murine and human T-cell lymphoma cells by rapamycin. (a) Real-time
measurement of the extracellular acidiﬁcation rate (ECAR) in glucose-free
media (no glucose), after addition of glucose (25 mM), oligomycin (1 μg/mL),
and 2-deoxyglucose (2-DG, 25mM). Data presented as mean± SD of
octuplicate measurements representative of at least three independent
experiments. (b) Determination of cellular lactate production, (c) glucose
uptake, and (d) intracellular ATP levels in control and rapamycin-treated cells.
Shown are mean± SD, n=3; **Po0.01.
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Figure 4. Inhibition of mTOR reduces expression of glycolysis genes in T-cell
lymphoma cells and xenograft tumors. mRNA expression levels of glucose
transporters 1 and 3 (GLUT1, GLUT3), hexokinase 2 (HK2), and lactate
dehydrogenase α (LDHA) in (a) cultured MBL2 cells, (b) cultured HH cells
(mean± SD, n=3), and (c) HH xenograft tumors (mean± SD, n=4 separate
tumors analyzed in triplicates). (d) Protein levels of GLUT1/3, HK2, and LDHA
in HH tumors correlate with the mRNA expression levels of respective gene
products. **Po0.01.
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of rapamycin-treated cells, we noted decreased sensitivity
to low-glucose conditions (Figure 5a). Although HH cells
seemed to be less sensitive to low-glucose conditions
compared with Hut78 cells, the overall trend of rapamycin
increasing viability in a low-glucose environment was notable
in both cell lines (Figure 5a). These data support the ﬁnding of
a reduced glycolytic state with less glucose utilization in
lymphoma cells when mTOR is inhibited.
Next, we asked whether the low-glucose resistance is
associated with an increased potential for compensatory
upregulation of mitochondrial oxidative phosphorylation
(OXPHOS). Although we did note an approximately 50%
reduction in the baseline oxygen consumption rate (OCR) in
rapamycin-treated versus control cells in normal glucose
media (Figure 5b), we did not observe a consistent difference
in the compensatory upregulation of OCR under low-glucose
conditions. Rapamycin-treated and control cells showed a
similar increase in baseline OCR in media with 1 and 0mM
glucose compared with normal media (Figure 5c). Further-
more, we did not ﬁnd a difference in ATP-linked respiration, a
measure for how much of the basal respiration was used to
synthesize ATP, between rapamycin-treated and control cells
(Figure 5d). Although baseline mitochondrial activity is also
lower after treatment with rapamycin, the potential to
upregulate OXPHOS under low-glucose conditions remains
unchanged, suggesting the need for intact mitochondrial
activity. To test this hypothesis, cells were treated with varying
concentrations of oligomycin and viability was assessed. We
observed a decrease in viability, indicating a dependence on
OXPHOS (Figure 5e). Notably, cells treated with rapamycin
also showed a marked reduction in viability, suggesting that
rapamycin-treated cells continue to rely on OXPHOS while
aerobic glycolysis is suppressed. We conclude that the
decreased metabolic demand after treatment with rapamycin
is matched by a metabolic phenotype with reduced glycolytic
state and continued reliance on mitochondrial OXPHOS.
DISCUSSION
In this study, we demonstrate the anti-tumor effect of
rapamycin in a mouse model of T-cell lymphoma. We show
that the inhibition of mTOR signaling alters the metabolic
phenotype of lymphoma cells by reducing their glycolytic
state and thus counteracting the Warburg effect of
cancer cells.
On the basis of earlier data demonstrating the activation of
mTOR in human CTCL cell lines, we sought to study the effect
of rapamycin as a way to control growth of lymphoma tumors.
Several reports demonstrate the activation of mTOR in human
CTCL cell lines and xenotransplanted tumors (Kremer et al.
2010; Marzec et al. 2011; Hu et al. 2014). Interestingly,
rapamycin was shown in one study to reduce proliferation
of the established human CTCL cell lines Hut78, MyLa, and
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SeAx cells, as well as cells freshly isolated from Sézary
patients. Furthermore, rapamycin reduced tumor size in a
MyLa-based xenotransplant model upon systemic administra-
tion (Kremer et al. 2010). In tissue samples of patients with
mycosis fungoides, activation of the mTOR/Akt axis was
shown by immunohistochemical means and seemed to
correlate with disease stage and a more aggressive disease
phenotype (Marzec et al. 2008; Levidou et al. 2013).
Our results indicating a shift of the metabolic phenotype
of T lymphoma cells after treatment with rapamycin are
consistent with accumulating evidence showing a central role
of mTOR signaling in regulating aerobic glycolysis in
T lymphocytes similar to its role in cancer. Through the
regulation of T-cell metabolism, the mTOR pathway is a
central regulator of lymphocyte activation and differentiation
into distinct lineages (Zeng and Chi 2013). T-cell activation
has been shown to be driven in an mTOR-dependent manner
by increasing glycolytic activity and upregulation of glycolytic
enzymes, whereas downregulation of those processes pro-
moted a regulatory phenotype (Shi et al. 2011). Thus, in
parallel to its role in cancer cells, mTOR has been shown to
regulate expression of several key glycolytic genes and the
glucose transporter 1 (GLUT-1) in normal lymphocytes in a
HIF1α- and Myc-dependent manner (Shi et al. 2011; Wang
et al. 2011).
The metabolic phenotype of rapamycin-treated lymphoma
cells with decreased glucose utilization and increased
resistance against low-glucose conditions may be of rele-
vance in the tumor microenvironment, as tumors commonly
display lower glucose concentrations than normal tissues
(Hirayama et al. 2009). Our ﬁndings highlight a common
problem with current anticancer treatments inducing a
quiescent, more robust phenotype that evades therapy.
Although rapidly dividing cells match their anabolic and
energetic requirements by aerobic glycolysis (Lunt and
Vander Heiden 2011), most slow-cycling cells rely on
mitochondrial OXPHOS to match their energetic demand
(Ward and Thompson 2012). The metabolic phenotype we
observed in HH and Hut78 cells with reliance on OXPHOS
and resistance against low-glucose conditions is thus con-
sistent with the metabolic features of treatment-resistant,
quiescent cells. Although rapamycin had a marked tumor
suppressive effect on T-cell lymphoma tumors including
xenografted human CTCL tumors, our study also demonstrates
that the metabolic phenotype of rapamycin-treated lym-
phoma cells displays characteristics that may contribute to
increased resistance in the tumor microenvironment and
against treatment. Our ﬁndings also demonstrate that those
cells rely on mitochondrial function with persistent sensitivity
to inhibition of mitochondrial OXPHOS. This may indicate a
potential therapeutic beneﬁt of OXPHOS inhibitors in
treatment regimens for cutaneous lymphoma similar to other
cancers (Wolf 2014). It should be noted, however, that the use
of established CTCL cell lines and xenotransplant models
creates limitations for conclusions about the clinical
applicability, which would have to be addressed by future
studies using freshly isolated lymphoma cells and normal
T cells as controls.
In conclusion, we provide evidence that rapamycin is able
to slow down growth of T-cell lymphoma tumors. Inhibition
of the mTOR pathway led to a shift of the metabolic
phenotype with a reduced glycolytic state and continued
dependence on mitochondrial function. Whether targeting of
speciﬁc metabolic pathways such as OXPHOS possesses
therapeutic potential in CTCL will be the subject of future
studies.
MATERIALS AND METHODS
Cell culture and reagents
MBL2 murine T–cell lymphoma cells (Wu et al. 2011) were cultured
in Dulbecco's modiﬁed Eagle's medium (Invitrogen, Waltham, MA)
with 10% heat-inactivated fetal bovine serum. Hut78 and HH cell
lines (ATCC, Manassas, VA) were cultured in Iscove's Modiﬁed
Dulbecco's Medium and RPMI 1640 (both from ATCC) with 10%
heat-inactivated fetal bovine serum. Where indicated, cells were
incubated with rapamycin (15 nM), oligomycin, or 2-deoxyglucose
all from Sigma-Aldrich (St Louis, MO).
Immunoblotting
Whole tumor and cell lysates were prepared in RIPA buffer (Sigma)
containing a protease inhibitor cocktail (Complete-mini, EDTA-free
protease inhibitor cocktail; Roche Applied Science, Indianapolis, IN).
Following electrophoresis and transfer to nitrocellulose sheets,
antibodies to S6K, pS6K (Thr389), S6, pS6 (S240/244), Akt, pAkt
(Ser473), HK2, and LDHA, all from Cell Signaling Technology
(Boston, MA), and GLUT1 and 3 (Abcam, Cambridge, MA) were used
for protein detection.
Animal studies
C57BL/6 mice and NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice
were purchased from Jackson Laboratory (Bar Harbor, ME). All
animal experiments were conducted in accordance with protocols
approved by the Institutional Animal Care and Usage Committee
(IACUC) at the Medical College of Wisconsin. For the syngeneic
T-cell lymphoma model, phosphate-buffered saline-washed MBL2
cells (4×105 in 20 μL phosphate-buffered saline) were injected into
C57BL/6 mouse ears as described before (Wu et al. 2011). Mice were
topically treated with dinitroﬂuorobenzene (DNFB, 0.5% in a
vehicle consisting of 4:1 (v/v) acetone and olive oil) (Fluka, Sigma-
Aldrich, St Louis, MO) to the injection site within 10minutes of
tumor cell inoculation. Starting on day 6, rapamycin 0.05% oint-
ment (rapamycin (sirolimus) oral solution 1mg/ml (Pﬁzer, New York,
NY) was mixed with an equal volume of white petrolatum)
was applied to ears daily until analysis on day 12. White
petrolatum without rapamycin was used as a vehicle control.
For the NSG mouse tumor assays, MBL2 (1× 106 in 200 μL PBS) or
HH cells (1×106 in 200 μL PBS) were injected into ﬂanks of
mice. Rapamycin treatment was started at a tumor size of 5×5mm
for 5 days (MBL2 tumors) or 10 days (HH tumors) of treatment.
For intraperitoneal injection of rapamycin (LC Laboratories), the
drug was reconstituted in absolute ethanol at 10 mg/ml and
diluted in 5% Tween 80 (Sigma) and 5% polyethylene glycol 400
(Hampton Research). Vehicle alone or rapamycin (4 mg/kg of body
weight) was injected daily. The ﬁnal volume of all injections
was 200 μl.
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Metabolic proﬁling
The Seahorse XF-96 Flux Analyzer (Seahorse Bioscience Inc.
Billerica, MA) was used to determine the metabolic proﬁle (ie the
oxygen consumption rate (OCR) and extracellular acidiﬁcation rate
(ECAR)) of cultured cells. Brieﬂy, 4× 104 MBL2 cells or 1×105 Hut78
or HH cells per well were seeded in 100 μL of Dulbecco's modiﬁed
Eagle's medium assay medium without sodium bicarbonate in a
V3-PET cell culture plate. An additional 80 μL of assay medium was
added prior to XF analysis. For the glycolytic stress test, cells were
kept in glucose-free DMEM for 1 hour after seeding followed by
analysis as shown. The rates of oxygen consumption and extra-
cellular acidiﬁcation were measured under basal conditions and after
addition of oligomycin (1 μg/mL) and 2-deoxyglucose (25mM) as
indicated.
Lactate production, glucose uptake, and ATP measurements
Lactate and ATP levels were measured using a lactate kit
(BioVision, Milpitas, CA) and the ATP-based CellTiter-Glo
assay (Promega, Madison, WI), respectively, following the manu-
facturer’s instructions. Luminescence was detected using a
Veritas Microplate Luminometer. Glucose uptake was deter-
mined using the Glucose Uptake Cell-Based Assay Kit (Cayman
Chemical, Ann Arbor, MI) following the manufacturer’s instruc-
tions. Data were acquired on a BD LSRII Flow Cytometer.
For all experiments, cells were treated with vehicle or rapamycin
(15 nM) overnight, and equal numbers of cells were used for
analysis.
Cell cycle and viability assays
For cell cycle analysis, cells were stained with Vybrant DyeCycle
Violet (DCV; Life Technologies, Grand Island, NY) according to the
manufacturer’s instructions. Data were acquired on a BD LSRII Flow
Cytometer and analyzed using Modﬁt software (Verity Software
House). For viability assays, cells were incubated with 7-AAD
(eBioscience, San Diego, CA), and data were acquired on a BD LSRII
Flow Cytometer.
RT-PCR
Total RNA was extracted from cell or tissue lysates using the RNeasy
kit (Qiagen, Valencia, CA) and then converted into complementary
DNA with the RT2 First Strand Kit (SA Bioscience). Real-time PCR was
performed on a StepOne Plus Real-time PCR system (Applied
Biosystem, Carlsbad, CA). All data presented were normalized for
beta-actin. Murine primer sequences: GLUT-1: forward CAGTTC
GGCTATAACACTGGTG; reverse GCCCCCGACAGAGAAGATG;
GLUT3: forward GATGACTCCAGTGTTGTAGCC; reverse AGACTT
GAGAACTAGGTTGGGA; HK2: forward GATCGCCTGCTTATTC
ACGG; reverse AACCGCCTAGAAATCTCCAGA; LDHA: forward
CATTGTCAAGTACAGTCCACACT; reverse TTCCAATTACTCGGTT
TTTGGGA ACTB: forward GACTCATCGTACTCCTGCTTG; reverse
GATTACTGCTCTGGCTCCTAG; Human primer sequences: GLUT-1:
forward GGATGAAGATGATGCTCAGC; reverse GTCACCCACAGC
CCTTC; GLUT3: forward GAAAGAGCCGATTGTAGCAAC; reverse
AAGACTTGAATTAGATTACAGCGATG; HK2: forward AGCCCTTT
CTCCATCTCCTT; reverse TCTGCTTGCCTACTTCTTCAC; LDHA:
forward GCAAGGAACACTAAGGAAGACA; reverse TGGGCTATTG
GACTCTCTGTA; ACTB: forward CCTTGCACATGCCGGAG; reverse
ACAGAGCCTCGCCTTTG.
Statistical analysis
Data are presented as mean± SD. P-values were calculated with
Student’s t test and considered signiﬁcant if less than 0.05.
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